Aslan Pharmaceuticals Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (2)

Latest Posts

About This Stock More About This Stock
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, December 7, 2019 5:15 PM EST
Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.
In this article: AZN, JNJ, MRK, CASI, ASLN
Read
Aslan Soars 186% After Journal Reports New Acute Myeloid Leukemia Data
Article By: The Fly
Saturday, November 23, 2019 11:10 AM EST
Aslan Pharmaceuticals announced that new preclinical data characterizing ASLAN003 as a potential treatment for acute myeloid leukemia has been published in the November issue of Haematologica Journal which sent shares surging higher.
In this article: ASLN
Read
Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months
Article By: ChinaBio® Today
Saturday, November 16, 2019 4:09 PM EST
Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.
In this article: HCM, BGNE, ASLN
Read
Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies
Article By: ChinaBio® Today
Saturday, March 2, 2019 4:14 PM EST
NJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts.
In this article: ASLN, BCAC
Read
Week In Review: China Life Science Starts Off 2019 With $425 Million In Deals
Article By: ChinaBio® Today
Sunday, January 13, 2019 1:18 PM EST
China's life science sector started off 2019 with $425 million from ten deals involving Apollomics, Schrödinger of New York City and BrightGene Bio-Medical of Suzhou, among others.
In this article: NVS, SPRO, CBMG, BHVN, ASLN
Read

PARTNER HEADLINES

Latest Tweets for $ASLN

No tweets yet!